Condition: Renal Function Disorder · Diabetic Macular Edema (DME) · Neovascular Age Related Macular Degeneration · Sponsor: University Hospital, Alexandroupolis
This study aims to investigate the impact of intravitreal injection of anti-vascular endothelial growth factor (anti VEGF) Faricimab on renal function of diabetic patients. Faricimab is a new anti-VEGF drug which inhibits both VEGF-A and Ang-2 and it is used for the treatment of diabetic macular edema and neovascular age related macular degeneration. It is known that previous anti-VEGF agents has systematic absorption and may cause deterioration in renal function of the patients. However, the effect of Faricimab on kidney function has not been investigated yet. Taking into account that Ang-2 has destructive effect on kidneys, the investigation of the effect of its inhibition in diabetic patients who have already renal function deterioration may provide a valuable information in scientific community.
This description comes directly from the study's public registry record.
Asli Perente, Dr · +306951577205 · asli_perende-90@hotmail.com
Always discuss trial participation with your own doctor first.
| University Hospital of Alexandroupolis | Alexandroupoli, Evros, Greece | Recruiting |
| University Hospital of Alexandroupolis | Alexandroupoli, Greece | Completed |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06929507